Arlington Partners LLC Purchases 1,981 Shares of Danaher Co. (NYSE:DHR)

Arlington Partners LLC raised its position in shares of Danaher Co. (NYSE:DHR) by 16.0% in the third quarter, HoldingsChannel reports. The firm owned 14,351 shares of the conglomerate’s stock after buying an additional 1,981 shares during the quarter. Arlington Partners LLC’s holdings in Danaher were worth $3,990,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Northwest Investment Counselors LLC bought a new stake in shares of Danaher during the 1st quarter valued at $193,000. AdvisorNet Financial Inc grew its holdings in Danaher by 11.3% during the first quarter. AdvisorNet Financial Inc now owns 758 shares of the conglomerate’s stock valued at $189,000 after purchasing an additional 77 shares during the period. Global Assets Advisory LLC purchased a new stake in Danaher in the first quarter worth about $40,656,000. CGN Advisors LLC bought a new position in shares of Danaher in the first quarter worth about $205,000. Finally, Strategic Planning Group LLC lifted its position in shares of Danaher by 18.1% during the 1st quarter. Strategic Planning Group LLC now owns 10,729 shares of the conglomerate’s stock valued at $2,679,000 after buying an additional 1,643 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock valued at $11,042,433 over the last three months. 11.10% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Stifel Nicolaus increased their target price on shares of Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. TD Cowen lifted their target price on shares of Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Stephens assumed coverage on shares of Danaher in a report on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 target price for the company. Leerink Partners raised their price target on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Finally, Robert W. Baird upped their price objective on Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $282.12.

Danaher Price Performance

Shares of Danaher stock traded down $3.62 during trading hours on Monday, reaching $270.76. The company’s stock had a trading volume of 557,585 shares, compared to its average volume of 2,707,091. The firm has a 50 day moving average price of $270.72 and a 200-day moving average price of $260.13. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The stock has a market cap of $200.55 billion, a P/E ratio of 46.51, a P/E/G ratio of 4.49 and a beta of 0.83. Danaher Co. has a one year low of $182.09 and a one year high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.15. The company had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm’s revenue for the quarter was down 2.9% on a year-over-year basis. During the same period in the previous year, the firm posted $2.05 earnings per share. On average, analysts predict that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a $0.27 dividend. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. Danaher’s dividend payout ratio is presently 18.31%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.